STIC Search Report
EIC 1700

STIC Database Tracking Number: 196099

TO:	From:
Deborah Lambkin **Location: REM/5B09/5C18** **Art Unit : 1626** **July 26, 2006** **Case Serial Number: 10/821705**	**Mei Huang** **Location: EIC 1700** **REMSEN 4B28** **Phone: 571/272-3952** **Mei.huang@uspto.gov**

Search Notes

Examiner Lambkin,

Please feel free to contact me if you have any questions or if you would like to refine the search query,

Thank you for using STIC services!

Mei Huang

Access DB# 196099

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: Deborah Lambkin Examiner #: 71300 Date: 7/20/06
Art Unit: 1626 Phone Number ~~30~~ 2-0693 Serial Number: ~~10/821,770~~ 10/821,705
Mail Box and Bldg/Room Location: 5C18/5B09 Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

****

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: _____

Inventors (please provide full names): _____

_____

Earliest Priority Filing Date: _____

For Sequence Searches Only *Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*

Please search genus of Cl I
+ species of claim 8

genus



species



all attachments

Please exclude inventors

Thanks

****

STAFF USE ONLY	Type of Search	Vendors and cost where applicable
Searcher: MAH	NA Sequence (#)	STN ✓
Searcher Phone #:	AA Sequence (#)	Dialog
Searcher Location:	Structure (#) 3	Questel/Orbit
Date Searcher Picked Up:	Bibliographic	Dr.Link
Date Completed: 7/25/06	Litigation	Lexis/Nexis
Searcher Prep & Review Time:	Fulltext	Sequence Systems
Clerical Prep Time:	Patent Family	WWW/Internet
Online Time:	Other	Other (specify)

PTO-1590 (8-01)

10/821,705

CLAIMS

What is claimed is:

1. A compound comprising



or a pharmaceutically acceptable salt or a prodrug thereof,

wherein

the dashed line represents the presence or absence of a double bond;

J is C=O or CHOH;

A is $-(CH_2)_6-$, or *cis* $-CH_2CH=CH-(CH_2)_3-$, wherein 1 or 2 carbons may be substituted with S or O;

B is CO_2H, or CO_2R, $CONR_2$, $CONHCH_2CH_2OH$, $CON(CH_2CH_2OH)_2$, CH_2OR, $P(O)(OR)_2$, $CONRSO_2R$, $SONR_2$, or



C/P/S/Cy

R is H, C_{1-6} alkyl;

D is $-(CH_2)_n-$, $-X(CH_2)_n$, or $-(CH_2)_nX-$, wherein n is from 0 to 3 and X is S or O; and

Cy

E is an aromatic or heteroaromatic moiety having from 0 to 4 substituents, said substituents each comprising from 1 to 6 non-hydrogen atoms.

2. The compound of claim 1 comprising



or a pharmaceutically acceptable salt or a prodrug thereof,

wherein G is CH_2, O, or S.

7. The compound of claim 1 comprising



or a pharmaceutically acceptable salt or a prodrug thereof.

8. The compound of claim 1 comprising



or a pharmaceutically acceptable salt or a prodrug thereof.

9. The compound of claim 1 comprising

STIC Search Results Feedback Form

USPTO

EIC17000

Questions about the scope or the results of the search? Contact *the EIC searcher or contact:*

Kathleen Fuller, EIC 1700 Team Leader
571/272-2505 REMSEN 4B28

Voluntary Results Feedback Form

- *I am an examiner in Workgroup:* ☐ *Example: 1713*
- *Relevant prior art* ***found****, search results used as follows:*
  - ☐ 102 rejection
  - ☐ 103 rejection
  - ☐ Cited as being of interest.
  - ☐ Helped examiner better understand the invention.
  - ☐ Helped examiner better understand the state of the art in their technology.

Types of relevant prior art found:

- ☐ Foreign Patent(s)
- ☐ Non-Patent Literature
  (journal articles, conference proceedings, new product announcements etc.)

- *Relevant prior art* ***not found:***
  - ☐ Results verified the lack of relevant prior art (helped determine patentability).
  - ☐ Results were not useful in determining patentability or understanding the invention.

Comments:

Drop off or send completed forms to EIC1700 REMSEN 4B28

```
=> fil reg
FILE 'REGISTRY' ENTERED AT 17:28:05 ON 25 JUL 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   25 JUL 2006  HIGHEST RN 895581-37-0
DICTIONARY FILE UPDATES:  25 JUL 2006  HIGHEST RN 895581-37-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> d his

     (FILE 'HOME' ENTERED AT 13:47:21 ON 25 JUL 2006)

     FILE 'HCAPLUS' ENTERED AT 13:47:41 ON 25 JUL 2006
                E US20050228185/PN
L1            1 S E3
                SEL RN

     FILE 'REGISTRY' ENTERED AT 13:49:21 ON 25 JUL 2006
L2           10 S E1-10

     FILE 'REGISTRY' ENTERED AT 14:07:21 ON 25 JUL 2006
L3                STR
L4                STR L3
L5                STR L4
L6                STR L5
L7            5 S L6
L8         1377 S L6 FUL
                SAV L8 LAM705/A
L9            3 S L2 AND L8
L10               STR L6
L11          40 S L10 SSS SAM SUB=L8
L12           1 S L2 AND C25H29CLO5S
L13               STR L10
L14           0 S L13 SSS SAM SUB=L8
L15           2 S L13 SSS FUL  SUB=L8
                SAV L15 LAM705S1/A
L16          11 S C25H29CLO5S/MF  <-- claim 8 compound
L17           2 S L8 AND L16

     FILE 'HCAPLUS' ENTERED AT 16:41:44 ON 25 JUL 2006
L18           1 S L15
L19           2 S L17
```

```
L20             2 S L18 OR L19

     FILE 'REGISTRY' ENTERED AT 16:43:01 ON 25 JUL 2006
L21               STR L13
L22             0 S L21 SSS SAM SUB=L8
L23               STR L10
L24            47 S L23 SSS SAM SUB=L8
L25               STR L23
L26            39 S L25 SSS SAM SUB=L8
L27             2 S L21 SSS FUL  SUB=L8
L28             2 S L15 OR L27
                  SAV L26 LAM705S2/A

     FILE 'REGISTRY' ENTERED AT 17:28:05 ON 25 JUL 2006

=> d l15 que stat
L6                STR
```



Ak~Cy @13 14 S~Ak~Cy @15 16 17 Ak~S~Cy @18 19 20 S~Cy @21 22



O~Ak~Cy @24 25 26 Ak~O~Cy @27 28 29 O~Cy @30 31

OH @32

```
VAR G1=13/15/18/21/23/24/27/30
VPA 32-1/5/4/3 U
VPA 7-1/5/4/3 U
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT   IS SAT  AT  13
GGCAT   IS UNS  AT  14
GGCAT   IS SAT  AT  16
GGCAT   IS UNS  AT  17
GGCAT   IS SAT  AT  18
GGCAT   IS UNS  AT  20
GGCAT   IS UNS  AT  22
GGCAT   IS UNS  AT  23
GGCAT   IS SAT  AT  25
GGCAT   IS UNS  AT  26
GGCAT   IS SAT  AT  27
GGCAT   IS UNS  AT  29
GGCAT   IS UNS  AT  31
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC   2
NUMBER OF NODES IS  31
```

STEREO ATTRIBUTES: NONE
L8 1377 SEA FILE=REGISTRY SSS FUL L6
L13 STR



VAR G1=13/15/18/21/23/24/27/30
VAR G2=7/33/38/43
VAR G3=C/P/S/51
VPA 48-5/4/3 U
VPA 49-5/4/3 U
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT IS SAT AT 13
GGCAT IS UNS AT 14
GGCAT IS SAT AT 16
GGCAT IS UNS AT 17
GGCAT IS SAT AT 18
GGCAT IS UNS AT 20
GGCAT IS UNS AT 22
GGCAT IS UNS AT 23
GGCAT IS SAT AT 25
GGCAT IS UNS AT 26
GGCAT IS SAT AT 27
GGCAT IS UNS AT 29
GGCAT IS UNS AT 31
GGCAT IS UNS AT 51
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS E6 C AT 49

GRAPH ATTRIBUTES:
RSPEC 2
NUMBER OF NODES IS 50

STEREO ATTRIBUTES: NONE
L15 2 SEA FILE=REGISTRY SUB=L8 SSS FUL L13

100.0% PROCESSED 227 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.02

=> fil hcap
FILE 'HCAPLUS' ENTERED AT 17:28:40 ON 25 JUL 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 Jul 2006 VOL 145 ISS 5
FILE LAST UPDATED: 24 Jul 2006 (20060724/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d l20 ibib abs hitstr hitind 1-2

L20 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:1103380 HCAPLUS
DOCUMENT NUMBER: 143:367143
TITLE: Preparation of 10-hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists
INVENTOR(S): Donde, Yariv
PATENT ASSIGNEE(S): Allergan, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 16 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005228185	A1	20051013	US 2004-821705	20040409
WO 2005100339	A1	20051027	WO 2005-US10124	20050325

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP,

the current application

KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD,
SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US,
UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC,
NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2004-821705 A 200404 09

OTHER SOURCE(S): MARPAT 143:367143
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Compd. I [dashed line = the presence or absence of a double bond; J = C=O, O, CHOH; A is (CH2)6, or cis CH2CH=CH(CH2)3, wherein 1 or 2 carbons may be substituted with S or O; B is CO2H, CO2R, CONR2, CONHCH2CH2OH, CON(CH2CH2OH)2, CH2OR, P(O)(OR)2, CONRSO2R, SONR2, 1-R-tetrazol-5-yl; R = H, C1-6-alkyl; D = (CH2)n, X(CH2)n, or (CH2)nX; n = 0 to 3; X = S, O; and E = arom. or heteroarom. moiety having from 0 to 4 substituents, said substituents each comprising from 1 to 6 non-hydrogen atoms] or a pharmaceutically acceptable salt or a prodrug thereof, is disclosed herein. Thus, prostaglandin analog II was prepd. from cyclopentenone III (TBDMS = Si Me2CMe3) via cuprate addn. of benzothiazole IV (TBDMS = Si Me2CMe3), desilylation/dehydration with AcOH in aq. THF, conjugate redn. with [Ph3PCuH]6, enol silylation with LDA/TMSCl, epoxidn./hydrolysis with dimethyldioxirane followed by pyridinium tosylate in aq. THF, desilylation with pyridinium hydrofluoride and enzymic hydrolysis with rabbit liver esterase. Methods, compns., and medicaments related thereto, as well as exptl. results showing prostaglandin EP4 selective agonist activity for certain compds. disclosed herein, are also disclosed. The binding affinity of II to prostaglandin receptors was detd. [Ki = 170-200 nM vs. EP4 receptor].

IT **866453-12-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and enzymic hydrolysis of; prepn. of 10-hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists)

RN 866453-12-5 HCAPLUS
CN 5-Heptenoic acid, 7-[(1R,5R)-5-[(1E)-5-(3-chlorobenzo[b]thien-2-yl)-3-hydroxy-1-pentenyl]-3-hydroxy-2-oxocyclopentyl]-, methyl ester, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT **866453-13-6P**
RL: BPN (Biosynthetic preparation); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 10-hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists)
RN 866453-13-6 HCAPLUS
CN 5-Heptenoic acid, 7-[(1R,5R)-5-[(1E)-5-(3-chlorobenzo[b]thien-2-yl)-3-hydroxy-1-pentenyl]-3-hydroxy-2-oxocyclopentyl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IC ICM A61K031-558
ICS C07D049-02; C07F009-28; C07D333-52
INCL 548253000; 554214000; 562008000; 562459000; 549049000
CC 26-3 (Biomolecules and Their Synthetic Analogs)
IT **866453-12-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and enzymic hydrolysis of; prepn. of 10-hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists)
IT **866453-13-6P**
RL: BPN (Biosynthetic preparation); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 10-hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists)

L20 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:888568 HCAPLUS
DOCUMENT NUMBER: 137:369893
TITLE: Preparation of prostanoic acid derivatives as ocular hypotensive agents

INVENTOR(S): Burk, Robert M.; Gac, Todd S.
PATENT ASSIGNEE(S): Allergan Sales, Inc., USA
SOURCE: PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002092099	A1	20021121	WO 2002-US14580	20020507
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002177620	A1	20021128	US 2001-859770	20010517
US 6531504	B2	20030311		
CA 2446994	AA	20021121	CA 2002-2446994	20020507
EP 1390036	A1	20040225	EP 2002-746356	20020507
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004530687	T2	20041007	JP 2002-589016	20020507
US 2003105155	A1	20030605	US 2002-294521	20021113
US 6670485	B2	20031230		

PRIORITY APPLN. INFO.: US 2001-859770 A 20010517
WO 2002-US14580 W 20020507

OTHER SOURCE(S): MARPAT 137:369893
GI



I



II

AB The present invention provides a method of treating ocular hypertension or glaucoma which comprises administering to an animal having ocular hypertension or glaucoma therapeutically effective amt. of prostanoic acid derivs. Title compds. (I) [wavy line attachments indicate either α or β configuration; dashed bonds represent a double bond or a single bond; D = a covalent bond, CH2, O, S, NH; X = CO2R, CONR2, CH2OR, P(O)(OR)2, CONRSO2R, SONR2, tetrazolyl; Y = O, OH, OCOR2, halogen, cyano; Z = CH2, a covalent bond; R = H, R2; R1 = H, R2, Ph, COR2; R2 = alkyl, alkenyl; R3 = (un)substituted benzothienyl, benzofuranyl, naphthyl], are prepd. Thus, prostanoic acid deriv. (II) was prepd. via a multistep synthetic sequence starting from 7-[(1R,2R,3R,5S)-2-formyl-3,5-bis[(tetrahydro-2H-pyran-2-yl)oxy]cyclopentyl]-methyl-(5Z)-heptenoate and [4-(3-chlorobenzo[b]thien-2-yl)-2-oxobutyl]-phosphonic acid di-Me ester. The prepd. compds. were tested and formulated.

IT **475467-34-6P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of prostanoic acid derivs. as ocular hypotensives)

RN 475467-34-6 HCAPLUS

CN 5-Heptenoic acid, 7-[(1R,2R,3R)-2-[(1E,3S)-5-(3-chlorobenzo[b]thien-2-yl)-3-hydroxy-1-pentenyl]-3-hydroxy-5-oxocyclopentyl]-, (5Z)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IC ICM A61K031-5575
ICS A61P027-06; C07C405-00

CC 26-3 (Biomolecules and Their Synthetic Analogs)
Section cross-reference(s): 1, 63

IT 25151-81-9DP, Prostanoic acid, derivs. **475467-34-6P**
475467-35-7P 475467-36-8P 475467-37-9P 475467-38-0P
475467-39-1P 475467-40-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of prostanoic acid derivs. as ocular hypotensives)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>

Simple search on a broadened query.


```
=> d l10 que stat
L6                STR
```



Ak~Cy @13 14

S~Ak~Cy @15 16 17

Ak~S~Cy @18 19 20

S~Cy @21 22



O~Ak~Cy @24 25 26

Ak~O~Cy @27 28 29

O~Cy @30 31

OH @32

```
VAR G1=13/15/18/21/23/24/27/30
VPA 32-1/5/4/3 U
VPA 7-1/5/4/3 U
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT   IS SAT  AT  13
GGCAT   IS UNS  AT  14
GGCAT   IS SAT  AT  16
GGCAT   IS UNS  AT  17
GGCAT   IS SAT  AT  18
GGCAT   IS UNS  AT  20
GGCAT   IS UNS  AT  22
GGCAT   IS UNS  AT  23
GGCAT   IS SAT  AT  25
GGCAT   IS UNS  AT  26
GGCAT   IS SAT  AT  27
GGCAT   IS UNS  AT  29
GGCAT   IS UNS  AT  31
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC   2
NUMBER OF NODES IS  31

STEREO ATTRIBUTES: NONE
L7          1377 SEA FILE=REGISTRY SSS FUL L6
L9               STR
```



None: in this query —OH could be attached to different positions.

```
VAR G1=13/15/18/21/23/24/27/30
VAR G2=7/33/38/43
VAR G3=C/P/S/54
VPA 32-5/4/3 U
VPA 48-5/4/3 U
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT   IS SAT  AT  13
GGCAT   IS UNS  AT  14
GGCAT   IS SAT  AT  16
GGCAT   IS UNS  AT  17
GGCAT   IS SAT  AT  18
GGCAT   IS UNS  AT  20
GGCAT   IS UNS  AT  22
GGCAT   IS UNS  AT  23
GGCAT   IS SAT  AT  25
GGCAT   IS UNS  AT  26
GGCAT   IS SAT  AT  27
GGCAT   IS UNS  AT  29
GGCAT   IS UNS  AT  31
DEFAULT ECLEVEL IS LIMITED
ECOUNT  IS E6 C  AT  52

GRAPH ATTRIBUTES:
RSPEC   1
NUMBER OF NODES IS  54

STEREO ATTRIBUTES: NONE
L10          39 SEA FILE=REGISTRY SUB=L7 SSS SAM L9

100.0% PROCESSED      69 ITERATIONS                    39 ANSWERS
```

SEARCH TIME: 00.00.01

PROJECTIONS (WITHIN SPECIFIED SUBSET):	ONLINE	**COMPLETE**
PROJECTED ITERATIONS (WITHIN SPECIFIED SUBSET):	882 TO	1878
PROJECTED ANSWERS (WITHIN SPECIFIED SUBSET):	406 TO	1154

=> d sca

L10 39 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Cyclopentaneheptanoic acid, 2-(4,4-difluoro-3-oxo-4-phenoxybutyl)-3-hydroxy-5-oxo-, methyl ester, [1R-(1α,2β,3α)]- (9CI)
MF C23 H30 F2 O6

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 39 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 5-Heptenoic acid, 7-[3-hydroxy-2-(3-hydroxy-4-phenoxy-1-butenyl)-5-oxocyclopentyl]-, 4-nitrophenyl ester, [1R-[1α(Z),2β(1E,3R*),3α]]- (9CI)
MF C28 H31 N O8

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 39 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4,5-Heptadienoic acid, 7-[3-hydroxy-2-(3-hydroxy-4-phenoxy-1-butenyl)-5-oxocyclopentyl]-, monosodium salt (9CI)
MF C22 H26 O6 . Na



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 39 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 5-Heptenoic acid, 7-[2-[6-(3,6-dihydro-4-methyl-1(2H)-pyridinyl)-3-hydroxy-6-oxo-1-hexenyl]-3-hydroxy-5-oxocyclopentyl]- (9CI)
MF C24 H35 N O6

PAGE 1-A



PAGE 2-A

Me

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 39 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 5-Heptenoic acid, 7-[2-[3-(4H-1,3-benzodioxin-2-yl)-3-hydroxypropyl]-3-hydroxy-5-oxocyclopentyl]-, methyl ester, [1R-[1α(Z),2β[R*(R*)],3α]]- (9CI)
MF C24 H32 O7

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 39 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 5-Heptenoic acid, 7-[3-hydroxy-2-(3-hydroxy-3-methyl-4-phenylbutyl)-5-oxocyclopentyl]-, [1,1'-biphenyl]-4-yl ester, [1R-[1α(Z),2β(S*),3α]]- (9CI)
MF C35 H40 O5

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0